Connective Tissue Disease-Associated Lung Disease

Immunology and Allergy Clinics of North America

Volumn 32, Issue 4, 2012, Pages 513-536

  Olson, Amy L ^a   Brown, Kevin K ^a   Fischer, Aryeh ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

Collagen vascular disease; Connective tissue disease; Interstitial lung disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE LUPUS PNEUMONITIS; ANKYLOSING SPONDYLITIS; AUTOIMMUNE LUNG DISEASE; AUTOINFLAMMATORY DISEASE; BRONCHIECTASIS; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SURVEILLANCE; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; GASTROESOPHAGEAL REFLUX; HUMAN; INTERSTITIAL LUNG DISEASE; LOEFFLER PNEUMONIA; LOWER RESPIRATORY TRACT; LUNG CARCINOMA; LUNG DISEASE; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG TOXICITY; MIXED CONNECTIVE TISSUE DISEASE; MUSCLE WEAKNESS; NONHODGKIN LYMPHOMA; PLEURA DISEASE; PLEURISY; PRIORITY JOURNAL; PSORIASIS; PULMONARY ASPIRATION; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID NODULE; SCLERODERMA; SHRINKING LUNG SYNDROME; SJOEGREN SYNDROME; SYNDROME OF ACUTE REVERSIBLE HYPOXEMIA; SYSTEMIC LUPUS ERYTHEMATOSUS; UPPER RESPIRATORY TRACT;

ARTHRITIS, RHEUMATOID; CONNECTIVE TISSUE DISEASES; HUMANS; LUNG DISEASES; LUNG DISEASES, INTERSTITIAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; POLYMYOSITIS; SJOGREN'S SYNDROME;

EID: 84868007528     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2012.09.002     Document Type: Review

References (118)

1. Fischer A., du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012, 380(9842):689-698.
2. Fischer A., du Bois R.M. A practical approach to connective tissue disease-associated lung disease 2012, Springer, New York. 2nd edition.
3. Frankel S.K., Brown K.K. Collagen vascular diseases of the lung. Clin Pulm Med 2006, 13(1):25-36.
4. Olson A.L., Brown K.K. Connective tissue disease-associated lung disorders. Eur Resp Mon 2009, 46:225-250.
5. Cottin V. Interstitial lung disease: are we missing formes frustes of connective tissue disease?. Eur Respir J 2006, 28(5):893-896.
6. Fischer A., Meehan R.T., Feghali-Bostwick C.A., et al. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest 2006, 130(4):976-981.
7. Fischer A., Solomon J.J., du Bois R.M., et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med 2012, 106(7):1040-1047.
8. Fischer A., Swigris J.J., du Bois R.M., et al. Minor salivary gland biopsy to detect primary Sjogren syndrome in patients with interstitial lung disease. Chest 2009, 136(4):1072-1078.
9. Fischer A., Swigris J.J., du Bois R.M., et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med 2009, 103(11):1719-1724.
10. Fischer A., West S.G., Swigris J.J., et al. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest 2010, 138(2):251-256.
11. Mittoo S., Gelber A.C., Christopher-Stine L., et al. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med 2009, 103(8):1152-1158.
12. Turesson C., Jacobsson L.T., Matteson E.L. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag 2008, 4(3):605-614.
13. Wolfe F., Caplan L., Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 2006, 54(2):628-634.
14. Carbone J., Perez-Rojas J., Sarmiento E. Infectious pulmonary complications in patients treated with anti-TNF-alpha monoclonal antibodies and soluble TNF receptor. Curr Infect Dis Rep 2009, 11(3):229-236.
15. Furst D.E. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum 2008, 39(5):327-346.
16. Alarcon G.S., Kremer J.M., Macaluso M., et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-lung study group. Ann Intern Med 1997, 127(5):356-364.
17. Camus P. Drug induced infiltrative lung diseases 2003, BC Decker, Inc, Hamilton (Ontario). Fourth edition.
18. Kremer J.M., Alarcon G.S., Weinblatt M.E., et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997, 40(10):1829-1837.
19. Lateef O., Shakoor N., Balk R.A. Methotrexate pulmonary toxicity. Expert Opin Drug Saf 2005, 4(4):723-730.
20. Malik S.W., Myers J.L., DeRemee R.A., et al. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996, 154(6 Pt 1):1851-1856.
21. Fischer A., Brown K.K., Frankel S.K. Treatment of connective tissue disease related interstitial lung disease. Clin Pulm Med 2009, 16(2):74-80.
22. Bedrossian C.W., Sussman J., Conklin R.H., et al. Azathioprine-associated interstitial pneumonitis. Am J Clin Pathol 1984, 82(2):148-154.
23. Morrissey P., Gohh R., Madras P., et al. Pulmonary fibrosis secondary to administration of mycophenolate mofetil. Transplantation 1998, 65(10):1414.
24. Shrestha N.K., Mossad S.B., Braun W. Pneumonitis associated with the use of mycophenolate mofetil. Transplantation 2003, 75(10):1762.
25. Koopman W.J. Dawn of the era of biologics in the treatment of the rheumatic diseases. Arthritis Rheum 2008, 58(Suppl 2):S75-S78.
26. Huggett M.T., Armstrong R. Adalimumab-associated pulmonary fibrosis. Rheumatology (Oxford) 2006, 45(10):1312-1313.
27. Ognenovski V.M., Ojo T.C., Fox D.A. Etanercept-associated pulmonary granulomatous inflammation in patients with rheumatoid arthritis. J Rheumatol 2008, 35(11):2279-2282.
28. Peno-Green L., Lluberas G., Kingsley T., et al. Lung injury linked to etanercept therapy. Chest 2002, 122(5):1858-1860.
29. Villeneuve E., St-Pierre A., Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol 2006, 33(6):1189-1193.
30. Zimmer C., Beiderlinden M., Peters J. Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis. Clin Rheumatol 2006, 25(3):430-432.
31. Steen V.D. The lung in systemic sclerosis. J Clin Rheumatol 2005, 11(1):40-46.
32. Doyle T.J., Hunninghake G.M., Rosas I.O. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med 2012, 185(11):1147-1153.
33. Gabbay E., Tarala R., Will R., et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 1997, 156(2 Pt 1):528-535.
34. Gochuico B.R., Avila N.A., Chow C.K., et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 2008, 168(2):159-166.
35. Launay D., Remy-Jardin M., Michon-Pasturel U., et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006, 33(9):1789-1801.
36. Uffmann M., Kiener H.P., Bankier A.A., et al. Lung manifestation in asymptomatic patients with primary Sjogren syndrome: assessment with high resolution CT and pulmonary function tests. J Thorac Imaging 2001, 16(4):282-289.
37. Steen V.D., Conte C., Owens G.R., et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994, 37(9):1283-1289.
38. LeRoy E.C., Black C., Fleischmajer R., et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988, 15(2):202-205.
39. Poormoghim H., Lucas M., Fertig N., et al. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000, 43(2):444-451.
40. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35(1):35-42.
41. Steen V.D., Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66(7):940-944.
42. Spagnolatti L., Zoia M.C., Volpini E., et al. Pulmonary function in patients with systemic sclerosis. Monaldi Arch Chest Dis 1997, 52(1):4-8.
43. Bjerke R.D., Tashkin D.P., Clements P.J., et al. Small airways in progressive systemic sclerosis (PSS). Am J Med 1979, 66(2):201-209.
44. Harrison N.K., Myers A.R., Corrin B., et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991, 144(3 Pt 1):706-713.
45. Cool C.D., Kennedy D., Voelkel N.F., et al. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997, 28(4):434-442.
46. Fischer A., Bull T.M., Steen V.D. Practical approach to screening for scleroderma-associated pulmonary arterial hypertension. Arthritis Care Res (Hoboken) 2012, 64(3):303-310.
47. Koh E.T., Lee P., Gladman D.D., et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996, 35(10):989-993.
48. Condliffe R., Kiely D.G., Peacock A.J., et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009, 179(2):151-157.
49. Highland K.B., Garin M.C., Brown K.K. The spectrum of scleroderma lung disease. Semin Respir Crit Care Med 2007, 28(4):418-429.
50. Bouros D., Wells A.U., Nicholson A.G., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002, 165(12):1581-1586.
51. Fischer A., Swigris J.J., Groshong S.D., et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest 2008, 134(3):601-605.
52. Kim D.S., Yoo B., Lee J.S., et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19(2):121-127.
53. Park J.H., Kim D.S., Park I.N., et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007, 175(7):705-711.
54. Wooten M. Systemic sclerosis and malignancy: a review of the literature. South Med J 2008, 101(1):59-62.
55. Rosenthal A.K., McLaughlin J.K., Linet M.S., et al. Scleroderma and malignancy: an epidemiological study. Ann Rheum Dis 1993, 52(7):531-533.
56. Hill C.L., Nguyen A.M., Roder D., et al. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003, 62(8):728-731.
57. Chatterjee S., Dombi G.W., Severson R.K., et al. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005, 52(8):2415-2424.
58. Derk C.T., Rasheed M., Artlett C.M., et al. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006, 33(6):1113-1116.
59. Bohan A., Peter J.B. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292(8):403-407.
60. Bohan A., Peter J.B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292(7):344-347.
61. Zantos D., Zhang Y., Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994, 21(10):1855-1859.
62. Schwarz M.I. The lung in polymyositis. Clin Chest Med 1998, 19(4):701-712. viii.
63. Solomon J., Swigris J.J., Brown K.K. J Bras Pneumol 2011, 37(1):100-109. [in English, Portuguese].
64. Schnabel A., Hellmich B., Gross W.L. Interstitial lung disease in polymyositis and dermatomyositis. Curr Rheumatol Rep 2005, 7(2):99-105.
65. Schnabel A., Reuter M., Biederer J., et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin Arthritis Rheum 2003, 32(5):273-284.
66. Arakawa H., Yamada H., Kurihara Y., et al. Nonspecific interstitial pneumonia associated with polymyositis and dermatomyositis: serial high-resolution CT findings and functional correlation. Chest 2003, 123(4):1096-1103.
67. Douglas W.W., Tazelaar H.D., Hartman T.E., et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001, 164(7):1182-1185.
68. Kang E.H., Lee E.B., Shin K.C., et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology (Oxford) 2005, 44(10):1282-1286.
69. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31(3):315-324.
70. Gabriel S.E., Crowson C.S., Kremers H.M., et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003, 48(1):54-58.
71. Minaur N.J., Jacoby R.K., Cosh J.A., et al. Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol Suppl 2004, 69:3-8.
72. Olson A.L., Swigris J.J., Sprunger D.B., et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011, 183(3):372-378.
73. Sihvonen S., Korpela M., Laippala P., et al. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004, 33(4):221-227.
74. Lawry G.V., Finerman M.L., Hanafee W.N., et al. Laryngeal involvement in rheumatoid arthritis. A clinical, laryngoscopic, and computerized tomographic study. Arthritis Rheum 1984, 27(8):873-882.
75. Metafratzi Z.M., Georgiadis A.N., Ioannidou C.V., et al. Pulmonary involvement in patients with early rheumatoid arthritis. Scand J Rheumatol 2007, 36(5):338-344.
76. Lieberman-Maran L., Orzano I.M., Passero M.A., et al. Bronchiectasis in rheumatoid arthritis: report of four cases and a review of the literature-implications for management with biologic response modifiers. Semin Arthritis Rheum 2006, 35(6):379-387.
77. White E.S., Tazelaar H.D., Lynch J.P. Bronchiolar complications of connective tissue diseases. Semin Respir Crit Care Med 2003, 24(5):543-566.
78. Perez T., Remy-Jardin M., Cortet B. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings. Am J Respir Crit Care Med 1998, 157(5 Pt 1):1658-1665.
79. Hayakawa H., Sato A., Imokawa S., et al. Bronchiolar disease in rheumatoid arthritis. Am J Respir Crit Care Med 1996, 154(5):1531-1536.
80. Kinoshita M., Higashi T., Tanaka C., et al. Follicular bronchiolitis associated with rheumatoid arthritis. Intern Med 1992, 31(5):674-677.
81. Devouassoux G., Cottin V., Liote H., et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J 2009, 33(5):1053-1061.
82. Cortet B., Flipo R.M., Remy-Jardin M., et al. Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1995, 54(10):815-819.
83. Hakala M., Paakko P., Huhti E., et al. Open lung biopsy of patients with rheumatoid arthritis. Clin Rheumatol 1990, 9(4):452-460.
84. Yousem S.A., Colby T.V., Carrington C.B. Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis 1985, 131(5):770-777.
85. Turesson C., O'Fallon W.M., Crowson C.S., et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis 2003, 62(8):722-727.
86. Kim E.J., Elicker B.M., Maldonado F., et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2010, 35(6):1322-1328.
87. Lee H.K., Kim D.S., Yoo B., et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005, 127(6):2019-2027.
88. Gizinski A.M., Mascolo M., Loucks J.L., et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol 2009, 28(5):611-613.
89. Swigris J.J., Fischer A., Gillis J., et al. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest 2008, 133(1):271-280.
90. Kinney W.W., Angelillo V.A. Bronchiolitis in systemic lupus erythematosus. Chest 1982, 82(5):646-649.
91. Fenlon H.M., Doran M., Sant S.M., et al. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol 1996, 166(2):301-307.
92. Wahl D.G., Guillemin F., de Maistre E., et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus 1997, 6(5):467-473.
93. Asherson R.A., Cervera R., Shepshelovich D., et al. Nonthrombotic manifestations of the antiphospholipid syndrome: away from thrombosis?. J Rheumatol 2006, 33(6):1038-1044.
94. Bertoli A.M., Vila L.M., Apte M., et al. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus 2007, 16(6):410-417.
95. Santos-Ocampo A.S., Mandell B.F., Fessler B.J. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest 2000, 118(4):1083-1090.
96. Zamora M.R., Warner M.L., Tuder R., et al. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997, 76(3):192-202.
97. Eagen J.W., Memoli V.A., Roberts J.L., et al. Pulmonary hemorrhage in systemic lupus erythematosus. Medicine (Baltimore) 1978, 57(6):545-560.
98. Toya S.P., Tzelepis G.E. Association of the shrinking lung syndrome in systemic lupus erythematosus with pleurisy: a systematic review. Semin Arthritis Rheum 2009, 39(1):30-37.
99. Fox R.I., Howell F.V., Bone R.C., et al. Primary sjogren syndrome: clinical and immunopathologic features. Semin Arthritis Rheum 1984, 14(2):77-105.
100. Mialon P., Barthelemy L., Sebert P., et al. A longitudinal study of lung impairment in patients with primary sjogren's syndrome. Clin Exp Rheumatol 1997, 15(4):349-354.
101. Mathieu A., Cauli A., Pala R., et al. Tracheo-bronchial mucociliary clearance in patients with primary and secondary sjogren's syndrome. Scand J Rheumatol 1995, 24(5):300-304.
102. Ito I., Nagai S., Kitaichi M., et al. Pulmonary manifestations of primary sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 2005, 171(6):632-638.
103. Deheinzelin D., Capelozzi V.L., Kairalla R.A., et al. Interstitial lung disease in primary sjogren's syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med 1996, 154(3 Pt 1):794-799.
104. Papathanasiou M.P., Constantopoulos S.H., Tsampoulas C., et al. Reappraisal of respiratory abnormalities in primary and secondary sjogren's syndrome. A controlled study. Chest 1986, 90(3):370-374.
105. Parambil J.G., Myers J.L., Lindell R.M., et al. Interstitial lung disease in primary sjogren syndrome. Chest 2006, 130(5):1489-1495.
106. Ioannidis J.P., Vassiliou V.A., Moutsopoulos H.M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary sjogren's syndrome. Arthritis Rheum 2002, 46(3):741-747.
107. Theander E., Henriksson G., Ljungberg O., et al. Lymphoma and other malignancies in primary sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006, 65(6):796-803.
108. Aringer M., Smolen J.S. Mixed connective tissue disease: what is behind the curtain?. Best Pract Res Clin Rheumatol 2007, 21(6):1037-1049.
109. Venables P.J. Mixed connective tissue disease. Lupus 2006, 15(3):132-137.
110. Mosca M., Neri R., Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 1999, 17(5):615-620.
111. Mosca M., Tani C., Carli L., et al. Undifferentiated CTD: a wide spectrum of autoimmune diseases. Best Pract Res Clin Rheumatol 2012, 26(1):73-77.
112. Mosca M., Tani C., Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a new frontier for rheumatology. Best Pract Res Clin Rheumatol 2007, 21(6):1011-1023.
113. Mosca M., Tani C., Neri C., et al. Undifferentiated connective tissue diseases (UCTD). Autoimmun Rev 2006, 6(1):1-4.
114. Mosca M., Tavoni A., Neri R., et al. Undifferentiated connective tissue diseases: the clinical and serological profiles of 91 patients followed for at least 1 year. Lupus 1998, 7(2):95-100.
115. Kinder B.W., Collard H.R., Koth L., et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?. Am J Respir Crit Care Med 2007, 176(7):691-697.
116. Nagai S., Kitaichi M., Itoh H., et al. Idiopathic nonspecific interstitial pneumonia/fibrosis: comparison with idiopathic pulmonary fibrosis and BOOP. Eur Respir J 1998, 12(5):1010-1019.
117. Corte T.J., Copley S.J., Desai S.R., et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 2012, 39(3):661-668.
118. Vij R., Noth I., Strek M.E. Autoimmune-featured interstitial lung disease: a distinct entity. Chest 2011, 140(5):1292-1299.